药片的形状和高度是否会影响液化床颗粒化活微生物在压缩过程中的生存?
Karl Vorländer1,2, Lukas Bahlmann1,2, Arno Kwade1,2
1Technische Universität Braunschweig, Institute for Particle Technology (iPAT), Volkmaroder Straße 5, 38104 Braunschweig, Germany.
International journal of pharmaceutics: X
|April 23, 2025
概括
温和的加工是益生菌生存能力的关键. 这项研究发现,较高的平板高度提高了Saccharomyces cerevisiae的存活率和平板强度,这可能是由于平板时弹性恢复减少.
科学领域:
- 制药技术 制药技术 制药技术
- 微生物学 微生物学
- 材料科学 材料科学 材料科学
背景情况:
- 有效的益生菌配方取决于保持微生物的生存能力.
- 液化床喷雾颗粒和片剂是益生菌的有希望的加工途径.
- 之前的研究集中在圆柱形平板电脑上,但为了更好地满足患者的要求,需要其他几何形状.
研究的目的:
- 为了研究药片几何形状在药片服用期间对Saccharomyces cerevisiae存活率的影响.
- 为了建立益生菌片生产的过程-结构-性质关系.
- 为了探索除了平坦圆筒外的替代药片形状,用于益生菌的管理.
主要方法:
- 使用不同的药片制作工具生产具有不同质量 (高度) 和凸起形状的平板,圆形药片.
- 在药片注射后确定Saccharomyces cerevisiae存活率.
- 测量片的物理机械性能,包括弹性回收和多孔性.
主要成果:
- 较高的药片高度与改善的微生物存活率和增强的机械强度相关.
- 在较高的平板电脑中,弹性恢复的减少有助于获得更好的结果.
- 药片形状的变化对微生物生存和机械性质的影响很小,因为整体孔隙性基本上不受影响.
结论:
- 药片的高度是影响益生菌活力和药片完整性的关键因素.
- 优化平板电脑的几何形状,特别是高度,可以提高有效益生菌配方的生产.
- 与优化平板电脑尺寸相比,对平板电脑工具设计的进一步研究可能会产生边际益处.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
835
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
835
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.9K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.9K
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
336
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
336
01:13In Vitro Drug Dissolution: Compendial Testing Models I
584
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
584
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
421
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
421